BioPharmX Corp fka BPMX

[Whos_Who]

BioPharmX is pleased to announce unaudited stockholders’ equity of approximately $6,278,000 on a pro forma basis as of January 16, 2018. Subject to review by the NYSE American LLC, the Company believes it is back in compliance with the NYSE American’s continued listing standards.

NYSE American Compliance
On December 1, 2017, the company received a deficiency letter from NYSE AMERICAN LLC ("NYSE American" or the "Exchange") stating that the company is not in compliance with the continued listing standards as set forth in Section 1003(f)(v) of the NYSE American Company Guide ("Company Guide"). The letter states that because the company's common stock had been selling for a low price per share for a substantial period of time, the company is not in compliance with Section 1003(f)(v) of the Company Guide. The NYSE American staff determined that the company's continued listing is predicated on it effecting a reverse stock split of its common stock or otherwise demonstrating sustained price improvement within a reasonable period of time, which the staff determined to be until June 1, 2018. In the interim, the company's common stock will continue to be listed on the NYSE American while it attempts to regain compliance with the listing standards, subject to the company's compliance with other continued listing requirements. The letter does not affect the company's business operations or its Securities and Exchange Commission reporting requirements.

NYSE MKT CONTINUED LISTING STANDARDS
https://www.google.com/url?sa=t&source=web&rct=j&url=https://www.nyse.com/publicdocs/nyse/markets/nyse-american/MKT_Continued_Listing_Standards.pdf&ved=2ahUKEwjl97_n193YAhUBWa0KHayxDmAQFjACegQIDxAB&usg=AOvVaw2pc7RckF2JVqxMLA0N8aEz